Ulcerative colitis is a chronic inflammatory bowel disease, with treatment goals aimed at controlling the inflammatory response, alleviating symptoms, preventing complications, and improving the quality of life for patients. Treatment plans must be customized based on the severity of the condition, the patient's age, and overall health status, typically combining medications, surgery, and lifestyle changes. Physicians will develop treatment strategies based on two phases: "control during flare-ups" and "maintenance during remission," emphasizing the importance of long-term follow-up.
During the treatment process, physicians will regularly assess the effectiveness of the therapy and adjust medications or treatment methods based on changes in the condition. Patients must closely cooperate with the healthcare team and actively report changes in symptoms to effectively control disease progression. The development of emerging biologics and personalized medical models has significantly improved patient prognosis, but treatment options still need to weigh the side effects of medications against long-term risks.
The current treatment strategy is divided into three main parts: medication, surgery, and adjunctive therapies. Medication primarily focuses on anti-inflammatory drugs, which are used in a stepwise manner based on the severity of the condition, categorized into first-line, second-line, and last-resort treatments. Surgical treatment is reserved for patients who do not respond to medications or have severe complications, with colectomy remaining the ultimate solution. Additionally, nutritional support, psychological counseling, and lifestyle adjustments are also important components of the overall treatment plan.
Treatment choices must follow the "stepwise treatment principle," where patients with mild conditions are prioritized for low side-effect medications, and treatment intensity is gradually escalated if the condition worsens or recurs. This model can reduce unnecessary side effects while ensuring treatment effectiveness. Physicians will dynamically adjust treatment plans based on endoscopic examinations, blood indices, and the severity of patient symptoms.
These drugs, such as mesalamine, are the first-line medications for mild to moderate ulcerative colitis and act directly on the intestinal mucosa to suppress inflammation. Oral formulations are suitable for proctitis or left-sided colitis, while rectal suppositories or enemas target rectal or sigmoid colon lesions. Common side effects include dizziness and diarrhea, and renal function should be monitored with long-term use.
Corticosteroids, such as prednisone, are commonly used during moderate to severe flare-ups to suppress systemic inflammatory responses, but long-term use is not advisable due to potential complications like osteoporosis or hyperglycemia. After remission, a shift to maintenance therapy is necessary to avoid rebound effects. Immunosuppressants like 6-MP or azathioprine can modulate the immune system and are usually combined with corticosteroids to accelerate remission, but regular monitoring of hematological indices is required.
New immunosuppressants like tocilizumab target specific inflammatory factors and are suitable for refractory cases that do not respond to traditional treatments. During use, close monitoring of liver function and infection risk is necessary, and physicians will adjust dosages based on treatment responses.
Surgical treatment is the last resort when pharmacological treatment fails. Total colectomy with ileoanal anastomosis can completely resolve intestinal issues, but lifelong follow-up for potential complications is necessary post-surgery. Some patients may opt for laparoscopic surgery to preserve the anus, but the risks of surgery and quality of life trade-offs must be evaluated.
Emerging research in regenerative medicine is exploring the therapeutic potential of mesenchymal stem cells, with animal studies showing promise in repairing intestinal mucosal damage, though clinical applications are still in experimental stages. Gene therapy and precision medicine are also research hotspots, with the potential to develop customized treatment plans targeting individual genetic characteristics in the future.
Nutritional management is a crucial aspect of treatment during remission, with a low-fiber diet recommended to reduce intestinal irritation. Some patients may need to control bloating with a low FODMAP diet. Nutritionists suggest a phased dietary adjustment approach to avoid sudden changes that could lead to nutritional imbalances. Exclusive enteral nutrition has been shown to induce remission in pediatric patients and can serve as an adjunctive measure for adults.
Stress management has been proven to reduce the frequency of flare-ups, with mindfulness meditation, yoga, and other calming therapies able to regulate the autonomic nervous system. Regular exercise can improve intestinal blood flow and immune modulation, with a recommendation of 150 minutes of moderate-intensity aerobic exercise per week, though vigorous exercise should be avoided during flare-ups.
Immunomodulatory therapies are rapidly evolving, with monoclonal antibody drugs targeting specific cytokines (such as anti-TNF-α agents) becoming standard treatments. New-generation small molecule drugs like JAK inhibitors can directly regulate signaling pathways. Gene editing technologies like CRISPR have shown potential in repairing inflammatory genes during laboratory stages, but clinical applications require extensive research validation.
Microecological therapy is another research focus, with probiotic formulations correcting gut microbiota imbalances currently in clinical trial phases. Artificial intelligence systems can analyze patient biomarkers to assist in predicting treatment responses, and personalized treatment will become a future trend. However, all new therapies must undergo rigorous clinical trials to ensure safety.
Immediate medical attention is required when the following warning symptoms occur: increased blood in stools, persistent fever exceeding 38.5°C, uncontrollable abdominal pain, or a sudden decrease in the effectiveness of traditional medications. Physicians may adjust medication dosages, perform endoscopic examinations, or arrange blood tests to assess inflammatory indices.
Regular follow-up checks should include blood counts, C-reactive protein, and intestinal endoscopic evaluations, with a recommendation for a complete assessment every 6-12 months. If medication treatment fails more than three times or if intestinal strictures or dysplasia (precancerous lesions) occur, surgical options should be discussed with a surgeon.
Biologics (such as anti-TNF-α drugs) may cause immune system-related side effects, such as increased risk of infections or skin reactions. Patients should regularly monitor blood indices, and if symptoms like fever, severe diarrhea, or unexplained fatigue occur, they should seek immediate medical attention. Doctors will adjust dosages or switch medications based on individual conditions.
How can patients reduce the risk of flare-ups through diet during remission?It is recommended to adopt an anti-inflammatory dietary pattern, such as increasing fiber (like oats, steamed vegetables), high-quality proteins (like fish, tofu), and avoiding high-fat, spicy foods, and alcohol. Personalized dietary adjustments should be made in conjunction with a nutritionist's assessment, as not all patients react the same way to the same foods.
Under what circumstances should consideration be given to surgical removal of the colon?When medication treatment fails, severe complications (such as significant bleeding, intestinal obstruction), or suspected precancerous lesions occur, total colectomy may be necessary. Although this surgery is a last resort, it can completely resolve intestinal damage issues, and patients will need to adapt to life with an ostomy.
Can long-term symptoms of ulcerative colitis lead to mental health issues?Yes, chronic pain, frequent bowel movements, and social stigma may trigger anxiety or depression. Patients should proactively communicate emotional changes with their physicians and be referred to mental health resources if necessary. Research shows that positive psychological interventions can improve treatment adherence.
Can vaccines be administered during treatment with biologics?Some live virus vaccines (such as varicella, measles) should be avoided, while influenza or pneumococcal vaccines are recommended to be administered during treatment intervals. The timing of vaccination should be confirmed with the physician to ensure vaccine efficacy and safety in the context of immunosuppressants.
%201.svg)
Copyright © 2025 MedFrontiers. All Rights Reserved.
